IP Library Granted Patent US 10,238,705
Granted Patent B2
US 10,238,705 · App. 14/934,940 · Granted Mar 26, 2019

Pharmaceutical composition and method of manufacturing

Inventor: Gary J. Speier (Eden Prairie, MN)
Assignee: CURE PHARMACEUTICAL HOLDING CORP.
A61K36/185A61K9/006A61K9/7023A61K31/05A61K31/352A61K36/00B01D11/0407A61K2236/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,238,705
App. No.
14/934,940
Granted
Mar 26, 2019
Kind
B2
Abstract

The present invention provides for methods of obtaining an extract of Cannabis plant material as well as subsequent processing of the extract to provide a concentrate of Cannabis . The present invention also provides for pharmaceutical dosage forms (e.g., oral thin films and transdermal patches) that include the concentrate (or extract) of Cannabis , as well as methods of medical treatment that include administering the pharmaceutical dosage forms.

Claims (50)

1. A process for obtaining a first concentrate of Cannabis sativa, Cannabis indica , or a combination thereof, enriched with tetrahydrocannabinols and a second concentrate of Cannabis sativa, Cannabis indica , or a combination thereof enriched with cannabidiols, the process comprising:

(a) contacting plant material comprising Cannabis sativa, Cannabis indica , or a combination thereof, with a supercritical fluid solvent system, at a pressure of about 750-3,000 psi, and at a temperature of about −20° C.-70° C., to provide an extract of Cannabis sativa, Cannabis indica , or a combination thereof; and

(b) removing the supercritical fluid solvent system from the extract:

wherein the (a) contacting of the plant material comprising Cannabis sativa, Cannabis indica , or a combination thereof, with the supercritical fluid solvent system and the (b) removing the supercritical fluid solvent system, is carried out two or more times, such that the process is a fractional supercritical fluid extraction;

wherein a first fractional supercritical fluid extraction is carried out such that (a) contacting of the plant material comprising Cannabis sativa, Cannabis indica , or a combination thereof, with the supercritical fluid solvent system is carried out at a pressure of about 750-1,500 psi and a temperature of about −20° C. to about 70° C. for a period of time of about 1-8 hours, to provide a first concentrate enriched with tetrahydrocannabinols;

wherein a second fractional supercritical fluid extraction is carried out such that (a) contacting of the plant material comprising Cannabis sativa, Cannabis indica , or a combination thereof, with the supercritical fluid solvent system is carried out at a pressure of about 1,500-3,000 psi and a temperature of about −20° C. to about 70° C., for a period of time of about 1-8 hours, to provide a second concentrate enriched with cannabidiols,

wherein each of the fractional supercritical fluid extractions are carried out at different pressures, at different temperatures, or both,

wherein one of the fractional supercritical fluid extractions is carried out at about 55° C.−65° C.

2. The method of claim 1 , wherein the first fractional supercritical fluid extraction is carried out in a solvent system that comprises carbon dioxide (CO 2 ) and at least one of hydrogen (H 2 ), neon (Ne), nitrogen (N 2 ), argon (Ar), methane (CH 4 ), ethane (CH 3 CH 3 ), propane (CH 3 CH 2 CH 3 ), ammonia (NH 3 ), water (H 2 O), xenon (Xe), methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran (THF), 1,4-dioxane, acetonitrile, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide (DMSO), formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane (Freon® 23), nitrous oxide (N 2 O), sulfur hexafluroide (SF 6 ), butane (n-C 4 H 10 ), isobutane (i-C 4 H 10 ), ethyl ether ((C 2 H 5 ) 2 O), benzotrifluoride (C 6 H 5 CF 3 ), (p-chlorophenyl)trifluoromethane (ClC 6 H 4 CF 3 ), chlorofluorocarbon (CFC), hydrofluorocarbon (HFA), and HFA-134a (1,1,1,2-tetrafluoroethane).

3. The method of claim 1 , wherein relative to the cannabis plant material, the first concentrate is enriched with tetrahydrocannabinols (THC), such that the first concentrate contains at least about a 10% higher concentration of tetrahydrocannabinols (THC).

4. The method of claim 1 , wherein the second fractional supercritical fluid extraction is carried out in a solvent system that comprises carbon dioxide (CO 2 ) and at least one of hydrogen (H 2 ), neon (Ne), nitrogen (N 2 ), argon (Ar), methane (CH 4 ), ethane (CH 3 CH 3 ), propane (CH 3 CH 2 CH 3 ), ammonia (NH 3 ), water (H 2 O), xenon (Xe), methanol, ethanol, 1-propanol, 2-propanol, 1-hexanol, 2-methoxy ethanol, tetrahydrofuran (THF), 1,4-dioxane, acetonitrile, methylene chloride, dichloroethane, chloroform, ethyl acetate, propylene carbonate, N,N-dimethylaceamide, dimethyl sulfoxide (DMSO), formic acid, carbon disulfide, acetone, toluene, hexanes, pentanes, trifluoromethane (Freon® 23), nitrous oxide (N 2 O), sulfur hexafluroide (SF 6 ), butane (n-C 4 H 10 ), isobutane (i-C 4 H 10 ), ethyl ether ((C 2 H 5 ) 2 O), benzotrifluoride (C 6 H 5 CF 3 ), (p-chlorophenyl)trifluoromethane (ClC 6 H 4 CF 3 ), chlorofluorocarbon (CFC), hydrofluorocarbon (HFA), and HFA-134a (1,1,1,2-tetrafluoroethane).

5. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with a different supercritical fluid solvent system.

6. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with a different supercritical fluid solvent system, each independently selected from: (i) polar aprotic, (ii) polar protic, (iii) nonpolar aprotic, and (iv) nonpolar protic.

7. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with the same supercritical fluid solvent system.

8. The process of claim 1 , wherein each fractional supercritical fluid extraction is carried out with the same supercritical fluid solvent system, selected from: (i) polar aprotic, (ii) polar protic, (iii) nonpolar aprotic, and (iv) nonpolar protic.

9. The method of claim 1 , wherein relative to the cannabis plant material, the cannabis concentrate is enriched with cannabidiol (CBD), such that the cannabis concentrate contains at least about a 10% higher concentration of cannabidiol (CBD).

10. The method of claim 1 , further comprising purifying the first concentrate of cannabis employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, and sublimation.

11. The method of claim 1 , further comprising purifying the second concentrate of cannabis employing at least one of chromatography, adsorption, crystallization, distillation, liquid-liquid extraction, filtration, fractional distillation, precipitation, recrystallization, and sublimation.

12. The method of claim 1 , wherein relative to the cannabis plant material, the first concentrate contains a lower concentration of at least one of (i)-(vi):

(i) cannabinol (CBN),

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids, and

(vi) hemp oil.

13. The method of claim 1 , wherein relative to the cannabis plant material, the first concentrate contains at least a 10% lower concentration of at least one of (i)-(vi):

(i) cannabinol (CBN),

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids, and

(vi) hemp oil.

14. The method of claim 1 , wherein relative to the cannabis plant material, the second concentrate contains a lower concentration of at least one of (i)-(vi):

(i) cannabinol (CBN),

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids, and

(vi) hemp oil.

15. The method of claim 1 , wherein relative to the cannabis plant material, the second concentrate contains at least a 10% lower concentration of at least one of (i)-(vi):

(i) cannabinol (CBN),

(ii) alkaloids,

(iii) terpenes,

(iv) terpenoids,

(v) cannabinoid acids, and

(vi) hemp oil.

16. The process of claim 1 , wherein the first fractional supercritical fluid extraction is carried out with carbon dioxide (CO 2 ) as the sole solvent.

17. The process of claim 1 , wherein the second fractional supercritical fluid extraction is carried out with carbon dioxide (CO 2 ) as the sole solvent.

18. The process of claim 1 , wherein the first concentrate is enriched with tetrahydrocannabinols (THCs), such that the first concentrate comprises at least about 90 wt. % tetrahydrocannabinols (THCs).

19. The process of claim 1 , wherein the second concentrate is enriched with cannabidiols (CBDs), such that the second concentrate comprises at least about 90 wt. % cannabidiols (CBDs).

Assignments (3)
SECURITY INTEREST Recorded Oct 18, 2024
From: AVENIR WELLNESS SOLUTIONS, INC.
To: SINDERBRAND LAW GROUP, PC
Reel/Frame 068937/0949 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2023
From: AVENIR WELLNESS SOLUTIONS, INC. F/K/A CURE PHARMACEUTICAL HOLDING CORPORATION
To: AVENIR WELLNESS SOLUTIONS, INC.
Reel/Frame 063663/0831 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: SPEIER, GARY J.
To: CURE PHARMACEUTICAL HOLDING CORP.
Reel/Frame 046512/0588 →
Continuity (4)
Continuation 14723980 · May 28, 2015
Continuation In Part 14255296 · Apr 17, 2014
Continuation In Part 14694303 · Apr 23, 2015
Related Publication 20160074451A1 · Mar 17, 2016
Cited By (4)
US 12,297,181 US 12,420,214 US 12,544,390 US 12,606,535